medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 1

<< Back Next >>

Ann Hepatol 2017; 16 (1)

A Summary of the 6th International Conference on Coagulation in Liver Disease: Discussion, Debate, Deliberations

Caldwell S, Intagliata N

Language: English
References: 96
Page: 12-15
PDF size: 122.75 Kb.


ABSTRACT

INTRODUCTION

Editor’s Preface from Nahum Mendez Sanchez: Below, the Editors of Annals of Hepatology provide a summary report from the 2015 multidisciplinary Coagulation in Liver Disease group meeting. This group which originated in 2005 is dedicated to issues of Coagulation, Hemostasis and Thrombosis in Liver Disease patients and includes members from diverse Specialties including representation from the fields of Hepatology, Hematology, Surgery, Anesthesiology, Pathology, Interventional Radiology, Laboratory Medicine, Transfusion Sciences and Blood Banking with a combined approach of basic and clinical Sciences. The aim of the symposium was to raise points of convergence of interest and research and to provide a forum to facilitate collaboration in order to advance the field.


REFERENCES

  1. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, Mannuccio Mannucci P. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-8.

  2. Hedner U. Recombinant activated factor VII: 30 years of research and innovation. Blood Reviews 2015; 29: S4-S8.

  3. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21: 1238-47.

  4. Giannini EG, Greco A, Marenco S, Andorno E, Valente U, Savarino V. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol 2010; 8: 899-902; quiz e109.

  5. Rijken DC, Kock EL, Guimaraes AH, Talens S, Darwish Murad S, Janssen HL, Leebeek FW. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. Journal of Thrombosis and Haemostasis. JTH 2012; 10: 2116-22.

  6. Hugenholtz GC, Macrae F, Adelmeijer J, Dulfer S, Porte RJ, Lisman T, Ariëns RA. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. Journal of thrombosis and haemostasis. JTH 2016; 14: 1054-66.

  7. Joist JH. AICF and DIC in liver cirrhosis: expressions of a hypercoagulable state. Am J Gastroenterol 1999; 94: 2801-3.

  8. Trotter JF, Olson J, Lefkowitz J, Smith AD, Arjal R, Kenison J. Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. American Journal of Transplantation. Official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2007; 7: 1624-28.

  9. Northup PG, Caldwell SH. Coagulation in liver disease: a guide for the clinician. Clin Gastroenterol Hepatol 2013; 11: 1064-74.

  10. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, Ariëns RA, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 44: 1039-46.

  11. Drolz A, Horvatits T, Roedl K, Rutter K, Staufer K, Kneidinger N, et al. Coagulation Parameters and Major Bleeding in Critically Ill Patients With Cirrhosis. Hepatology 2016; 64: 556-68.

  12. Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Alimentary pharmacology & therapeutics 2007; 26: 141-8.

  13. De Pietri L, Bianchini M, Montalti R, De Maria N, Di Maira T, Begliomini B, Gerunda GE, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology 2016; 63: 566-73.

  14. Lemoinne S, Thabut D, Housset C, Moreau R, Valla D, Boulanger CM, Rautou PE. The emerging roles of microvesicles in liver diseases. Nature Reviews Gastroenterology & Hepatology 2014; 11: 350-61.)

  15. Jenne CN, Kubes P. Immune surveillance by the liver. Nature Immunology 2013; 14: 996-1006.

  16. Kopec AK, Joshi N, Luyendyk JP. Role of hemostatic factors in hepatic injury and disease: animal models de-liver. Journal of Thrombosis and Haemostasis. JTH 2016; 14: 1337-49.

  17. Kavanagh C, Shaw S, Webster CR. Coagulation in hepatobiliary disease. Journal of Veterinary Emergency and Critical Care 2011; 21: 589-604.

  18. Valla D. Splanchnic Vein Thrombosis. Seminars in thrombosis and hemostasis 2015; 41: 494-502.

  19. Rautou PE, Douarin L, Denninger MH, Escolano S, Lebrec D, Moreau R, Vidaud M, et al. Bleeding in patients with Budd- Chiari syndrome. J Hepatol 2011; 54: 56-63.

  20. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61.

  21. Tripodi A, Primignani M, Lemma L, Chantarangkul V, Dell’Era A, Iannuzzi F, Aghemo A, et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology 2010; 52: 249-55.

  22. Stravitz RT, Lisman T, Luketic VA, Sterling RK, Puri P, Fuchs M, Ibrahim A, et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2012; 56: 129-36.

  23. Northup PG, Argo CK, Shah N, Caldwell SH. Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications. Semin Liver Dis 2012; 32: 39-48.

  24. Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143: 1253-60 e1251-4.

  25. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, Mannuccio Mannucci P. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-8.

  26. Hedner U. Recombinant activated factor VII: 30 years of research and innovation. Blood Reviews 2015; 29: S4-S8.

  27. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21: 1238-47.

  28. Giannini EG, Greco A, Marenco S, Andorno E, Valente U, Savarino V. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol 2010; 8: 899-902; quiz e109.

  29. Rijken DC, Kock EL, Guimaraes AH, Talens S, Darwish Murad S, Janssen HL, Leebeek FW. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. Journal of Thrombosis and Haemostasis. JTH 2012; 10: 2116-22.

  30. Hugenholtz GC, Macrae F, Adelmeijer J, Dulfer S, Porte RJ, Lisman T, Ariëns RA. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. Journal of thrombosis and haemostasis. JTH 2016; 14: 1054-66.

  31. Joist JH. AICF and DIC in liver cirrhosis: expressions of a hypercoagulable state. Am J Gastroenterol 1999; 94: 2801-3.

  32. Trotter JF, Olson J, Lefkowitz J, Smith AD, Arjal R, Kenison J. Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. American Journal of Transplantation. Official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2007; 7: 1624-28.

  33. Northup PG, Caldwell SH. Coagulation in liver disease: a guide for the clinician. Clin Gastroenterol Hepatol 2013; 11: 1064-74.

  34. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, Ariëns RA, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 44: 1039-46.

  35. Drolz A, Horvatits T, Roedl K, Rutter K, Staufer K, Kneidinger N, et al. Coagulation Parameters and Major Bleeding in Critically Ill Patients With Cirrhosis. Hepatology 2016; 64: 556-68.

  36. Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Alimentary pharmacology & therapeutics 2007; 26: 141-8.

  37. De Pietri L, Bianchini M, Montalti R, De Maria N, Di Maira T, Begliomini B, Gerunda GE, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology 2016; 63: 566-73.

  38. Lemoinne S, Thabut D, Housset C, Moreau R, Valla D, Boulanger CM, Rautou PE. The emerging roles of microvesicles in liver diseases. Nature Reviews Gastroenterology & Hepatology 2014; 11: 350-61.)

  39. Jenne CN, Kubes P. Immune surveillance by the liver. Nature Immunology 2013; 14: 996-1006.

  40. Kopec AK, Joshi N, Luyendyk JP. Role of hemostatic factors in hepatic injury and disease: animal models de-liver. Journal of Thrombosis and Haemostasis. JTH 2016; 14: 1337-49.

  41. Kavanagh C, Shaw S, Webster CR. Coagulation in hepatobiliary disease. Journal of Veterinary Emergency and Critical Care 2011; 21: 589-604.

  42. Valla D. Splanchnic Vein Thrombosis. Seminars in thrombosis and hemostasis 2015; 41: 494-502.

  43. Rautou PE, Douarin L, Denninger MH, Escolano S, Lebrec D, Moreau R, Vidaud M, et al. Bleeding in patients with Budd- Chiari syndrome. J Hepatol 2011; 54: 56-63.

  44. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61.

  45. Tripodi A, Primignani M, Lemma L, Chantarangkul V, Dell’Era A, Iannuzzi F, Aghemo A, et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology 2010; 52: 249-55.

  46. Stravitz RT, Lisman T, Luketic VA, Sterling RK, Puri P, Fuchs M, Ibrahim A, et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2012; 56: 129-36.

  47. Northup PG, Argo CK, Shah N, Caldwell SH. Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications. Semin Liver Dis 2012; 32: 39-48.

  48. Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143: 1253-60 e1251-4.

  49. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, Mannuccio Mannucci P. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-8.

  50. Hedner U. Recombinant activated factor VII: 30 years of research and innovation. Blood Reviews 2015; 29: S4-S8.

  51. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21: 1238-47.

  52. Giannini EG, Greco A, Marenco S, Andorno E, Valente U, Savarino V. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol 2010; 8: 899-902; quiz e109.

  53. Rijken DC, Kock EL, Guimaraes AH, Talens S, Darwish Murad S, Janssen HL, Leebeek FW. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. Journal of Thrombosis and Haemostasis. JTH 2012; 10: 2116-22.

  54. Hugenholtz GC, Macrae F, Adelmeijer J, Dulfer S, Porte RJ, Lisman T, Ariëns RA. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. Journal of thrombosis and haemostasis. JTH 2016; 14: 1054-66.

  55. Joist JH. AICF and DIC in liver cirrhosis: expressions of a hypercoagulable state. Am J Gastroenterol 1999; 94: 2801-3.

  56. Trotter JF, Olson J, Lefkowitz J, Smith AD, Arjal R, Kenison J. Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. American Journal of Transplantation. Official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2007; 7: 1624-28.

  57. Northup PG, Caldwell SH. Coagulation in liver disease: a guide for the clinician. Clin Gastroenterol Hepatol 2013; 11: 1064-74.

  58. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, Ariëns RA, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 44: 1039-46.

  59. Drolz A, Horvatits T, Roedl K, Rutter K, Staufer K, Kneidinger N, et al. Coagulation Parameters and Major Bleeding in Critically Ill Patients With Cirrhosis. Hepatology 2016; 64: 556-68.

  60. Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Alimentary pharmacology & therapeutics 2007; 26: 141-8.

  61. De Pietri L, Bianchini M, Montalti R, De Maria N, Di Maira T, Begliomini B, Gerunda GE, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology 2016; 63: 566-73.

  62. Lemoinne S, Thabut D, Housset C, Moreau R, Valla D, Boulanger CM, Rautou PE. The emerging roles of microvesicles in liver diseases. Nature Reviews Gastroenterology & Hepatology 2014; 11: 350-61.)

  63. Jenne CN, Kubes P. Immune surveillance by the liver. Nature Immunology 2013; 14: 996-1006.

  64. Kopec AK, Joshi N, Luyendyk JP. Role of hemostatic factors in hepatic injury and disease: animal models de-liver. Journal of Thrombosis and Haemostasis. JTH 2016; 14: 1337-49.

  65. Kavanagh C, Shaw S, Webster CR. Coagulation in hepatobiliary disease. Journal of Veterinary Emergency and Critical Care 2011; 21: 589-604.

  66. Valla D. Splanchnic Vein Thrombosis. Seminars in thrombosis and hemostasis 2015; 41: 494-502.

  67. Rautou PE, Douarin L, Denninger MH, Escolano S, Lebrec D, Moreau R, Vidaud M, et al. Bleeding in patients with Budd- Chiari syndrome. J Hepatol 2011; 54: 56-63.

  68. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61.

  69. Tripodi A, Primignani M, Lemma L, Chantarangkul V, Dell’Era A, Iannuzzi F, Aghemo A, et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology 2010; 52: 249-55.

  70. Stravitz RT, Lisman T, Luketic VA, Sterling RK, Puri P, Fuchs M, Ibrahim A, et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2012; 56: 129-36.

  71. Northup PG, Argo CK, Shah N, Caldwell SH. Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications. Semin Liver Dis 2012; 32: 39-48.

  72. Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143: 1253-60 e1251-4.

  73. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, Mannuccio Mannucci P. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-8.

  74. Hedner U. Recombinant activated factor VII: 30 years of research and innovation. Blood Reviews 2015; 29: S4-S8.

  75. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21: 1238-47.

  76. Giannini EG, Greco A, Marenco S, Andorno E, Valente U, Savarino V. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol 2010; 8: 899-902; quiz e109.

  77. Rijken DC, Kock EL, Guimaraes AH, Talens S, Darwish Murad S, Janssen HL, Leebeek FW. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. Journal of Thrombosis and Haemostasis. JTH 2012; 10: 2116-22.

  78. Hugenholtz GC, Macrae F, Adelmeijer J, Dulfer S, Porte RJ, Lisman T, Ariëns RA. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. Journal of thrombosis and haemostasis. JTH 2016; 14: 1054-66.

  79. Joist JH. AICF and DIC in liver cirrhosis: expressions of a hypercoagulable state. Am J Gastroenterol 1999; 94: 2801-3.

  80. Trotter JF, Olson J, Lefkowitz J, Smith AD, Arjal R, Kenison J. Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. American Journal of Transplantation. Official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2007; 7: 1624-28.

  81. Northup PG, Caldwell SH. Coagulation in liver disease: a guide for the clinician. Clin Gastroenterol Hepatol 2013; 11: 1064-74.

  82. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, Ariëns RA, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 44: 1039-46.

  83. Drolz A, Horvatits T, Roedl K, Rutter K, Staufer K, Kneidinger N, et al. Coagulation Parameters and Major Bleeding in Critically Ill Patients With Cirrhosis. Hepatology 2016; 64: 556-68.

  84. Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Alimentary pharmacology & therapeutics 2007; 26: 141-8.

  85. De Pietri L, Bianchini M, Montalti R, De Maria N, Di Maira T, Begliomini B, Gerunda GE, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology 2016; 63: 566-73.

  86. Lemoinne S, Thabut D, Housset C, Moreau R, Valla D, Boulanger CM, Rautou PE. The emerging roles of microvesicles in liver diseases. Nature Reviews Gastroenterology & Hepatology 2014; 11: 350-61.)

  87. Jenne CN, Kubes P. Immune surveillance by the liver. Nature Immunology 2013; 14: 996-1006.

  88. Kopec AK, Joshi N, Luyendyk JP. Role of hemostatic factors in hepatic injury and disease: animal models de-liver. Journal of Thrombosis and Haemostasis. JTH 2016; 14: 1337-49.

  89. Kavanagh C, Shaw S, Webster CR. Coagulation in hepatobiliary disease. Journal of Veterinary Emergency and Critical Care 2011; 21: 589-604.

  90. Valla D. Splanchnic Vein Thrombosis. Seminars in thrombosis and hemostasis 2015; 41: 494-502.

  91. Rautou PE, Douarin L, Denninger MH, Escolano S, Lebrec D, Moreau R, Vidaud M, et al. Bleeding in patients with Budd- Chiari syndrome. J Hepatol 2011; 54: 56-63.

  92. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61.

  93. Tripodi A, Primignani M, Lemma L, Chantarangkul V, Dell’Era A, Iannuzzi F, Aghemo A, et al. Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. Hepatology 2010; 52: 249-55.

  94. Stravitz RT, Lisman T, Luketic VA, Sterling RK, Puri P, Fuchs M, Ibrahim A, et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2012; 56: 129-36.

  95. Northup PG, Argo CK, Shah N, Caldwell SH. Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications. Semin Liver Dis 2012; 32: 39-48.

  96. Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143: 1253-60 e1251-4.




2020     |     www.medigraphic.com